Clinical studies of CS-866, the newest angiotensin II receptor antagonist.
about
Management of Hypertension Using Olmesartan Alone or in CombinationWIN OVER study: Efficacy and safety of olmesartan in Indian hypertensive patients: results of an open label, non-comparative, multi-centric, post marketing observational studyHypertension management in 2002: where have we been? where might we be going?Strategies to meet lower blood pressure goals with a new standard in angiotensin II receptor blockade.A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations?Olmesartan medoxomil: the seventh angiotensin receptor antagonist.Impact of olmesartan on blood pressure, endothelial function, and cardiovascular outcomes.Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertensionOlmesartan medoxomil: current status of its use in monotherapy.Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combinationBlood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study.Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide.Olmesartan medoxomil: recent clinical and experimental acquisitions.Severe Hyponatremia Associated with the Use of Angiotensin II Receptor Blocker/thiazide Combinations.Beating the clock: reducing cardiovascular risk by rapid blood pressure reduction with olmesartan.Olmesartan medoxomil-based therapy for the management of hypertension.In situ intestinal permeability and in vivo absorption characteristics of olmesartan medoxomil in self-microemulsifying drug delivery system.Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension.Olmesartan for the treatment of arterial hypertension.Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and cAngiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.The use of modeling and simulation to guide clinical development of olmesartan medoxomil in pediatric subjects.Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension.Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients.Initial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertension.Comparison of the Efficacy of Morning versus Evening Administration of Olmesartan in Uncomplicated Essential Hypertension
P2860
Q33734043-C74562EF-5F11-4C4E-B045-00D0AE08C3D1Q34002218-7539EBB0-CDD3-4CC1-927C-F1F4A089F76BQ34970359-1BF10856-D8B1-4B13-8C54-A7AB66B3BA51Q34970370-3F39A5F7-8636-41C5-B9BE-5C2AB120831DQ35013827-55294C61-49BA-461B-8882-3B9ABFE10EA4Q35035096-969E77EA-53E7-4E95-A6EB-3A3321A7F3AFQ35210513-42DF630B-947F-48C6-B036-FF6AD75A1094Q36013049-FD8FBD88-1B73-44F3-9372-F95022BA224CQ36013054-C778DD39-5875-491F-B3CB-EFF3ED37B88AQ36835866-A885B499-D92C-4682-8A6A-F0715F1E317BQ37343667-1E972EF7-1D6F-4118-B843-E270E3EBB3F6Q37417689-57479EB5-A753-4B05-9F1E-4680A8362158Q37581623-175540B2-101A-4A4E-9235-60E11E0E50E9Q37631017-15C2E01D-B4D5-4771-AD98-5154FD0AED04Q37743464-B9815DE1-9E72-4D47-9076-B1D3815C39AFQ38178325-37249BB7-7FCC-4F3B-98DC-4BBDD3ACE6EAQ38469693-25683292-4C03-4E7A-9D2D-75E0129D4F1EQ39479847-6FA0B4AC-22EF-462E-A085-1208D8DF2229Q40076763-11D3E4A2-30C7-48A8-8066-F3A5678DF1C5Q42621178-5712DC05-1037-4E00-91E7-8AC546D3B454Q43288456-482D23FE-BBEE-4727-AAA5-0A8F770DC2B1Q43954254-8B971399-A020-4100-867F-32C84B7A6BD9Q44452204-E24B9160-1122-42B1-BB14-77D186B493D5Q46163937-26BF4EFB-7260-415B-9FA1-520D7A2780D0Q46923755-2745D61F-2D2D-4EA7-BADC-5119AE0DC760Q57987801-D83882D2-5C06-4E35-A189-82718B2B22EF
P2860
Clinical studies of CS-866, the newest angiotensin II receptor antagonist.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Clinical studies of CS-866, the newest angiotensin II receptor antagonist.
@ast
Clinical studies of CS-866, the newest angiotensin II receptor antagonist.
@en
Clinical studies of CS-866, the newest angiotensin II receptor antagonist.
@nl
type
label
Clinical studies of CS-866, the newest angiotensin II receptor antagonist.
@ast
Clinical studies of CS-866, the newest angiotensin II receptor antagonist.
@en
Clinical studies of CS-866, the newest angiotensin II receptor antagonist.
@nl
prefLabel
Clinical studies of CS-866, the newest angiotensin II receptor antagonist.
@ast
Clinical studies of CS-866, the newest angiotensin II receptor antagonist.
@en
Clinical studies of CS-866, the newest angiotensin II receptor antagonist.
@nl
P1476
Clinical studies of CS-866, the newest angiotensin II receptor antagonist.
@en
P2093
J M Neutel
P304
P356
10.1016/S0002-9149(01)01510-7
P407
P577
2001-04-01T00:00:00Z